- Immunodiagnostics group Oncimmune Holdings said its Spanish distributor, Sabartech, hade signed a new supply agreement with Quironsalud.

The agreement would involve Oncimmune's EarlyCDT-Lung technology being used as a screening test for the early detection of lung cancer through Quironsalud's hospitals and clinics in Spain.

Quironsalud operated the largest private hospital network in Spain, with 46 hospitals, 56 outpatient centres and some 300 occupational risk centres.

'Today's announcement marks another positive step in realising the commercial value of our first marketed test, EarlyCDT-Lung, based on the recognition of its ability to detect cancer four years or more earlier than standard diagnosis,' chief executive Adam M Hill said.

'With more than £33m in minimum sales commitments over the next five years, we look forward to providing further updates on sales growth.'

'Today's announcement also validates our strategy of accelerating value creation through partnering.'

At 9:58am: [LON:ONC] Oncimmune Holdings Plc share price was 0p at 85p

Story provided by